Contrasting Lisata Therapeutics (LSTA) & Its Competitors

Lisata Therapeutics (NASDAQ:LSTA) is one of 846 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Lisata Therapeutics to similar businesses based on the strength of its institutional ownership, analyst recommendations, earnings, profitability, dividends, risk and valuation.

Institutional and Insider Ownership

8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 47.7% of shares of all “Biotechnology” companies are held by institutional investors. 8.4% of Lisata Therapeutics shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Lisata Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Lisata Therapeutics’ rivals have a beta of 1.14, suggesting that their average share price is 14% more volatile than the S&P 500.

Valuation and Earnings

This table compares Lisata Therapeutics and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lisata Therapeutics	$170,000.00	-$16.59 million	-0.73
Lisata Therapeutics Competitors	$729.47 million	$11.46 million	-14.95

Lisata Therapeutics’ rivals have higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Lisata Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-116.08%	-90.55%
Lisata Therapeutics Competitors	-12,285.98%	-196.04%	-30.61%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Lisata Therapeutics and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1	2	0	0	1.67
Lisata Therapeutics Competitors	9904	15277	45626	1595	2.54

As a group, “Biotechnology” companies have a potential upside of 120.72%. Given Lisata Therapeutics’ rivals stronger consensus rating and higher probable upside, analysts clearly believe Lisata Therapeutics has less favorable growth aspects than its rivals.

Summary

Lisata Therapeutics rivals beat Lisata Therapeutics on 10 of the 13 factors compared.

About Lisata Therapeutics

Lisata Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for solid tumors. The company’s approach is designed to improve the delivery and effectiveness of cancer treatments by targeting the tumor microenvironment, which can limit the penetration of medicines into tumors. Lisata’s lead investigational product is certepetide, formerly known as CEND-1. Certepetide is a tumor-penetrating peptide intended to selectively home to tumor tissue and temporarily modify the tumor microenvironment, potentially helping co-administered anticancer therapies reach cancer cells more effectively.